Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

PARPs (Poly(ADP-Ribose) Polymerases) Inhibitors & Ovarian cancer

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Poly (ADP-ribose) polymerase inhibitors (PARPis) have reshaped the treatment scenario of metastatic Ovarian cancer in the maintenance setting post platinum-based chemotherapy.
Maiorano et al. 2023 Pharmaceuticals (Basel) 16(9): 1261

…

References (Sources)

Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors
Lee & Matulonis 2020 Exp Opin Emerging Drugs 25: 165-188
Review
Parp Inhibitors for the Treatment of Ovarian Cancer
Cortesi et al. 2018 Current Cancer Drug Targets 18: 877-893
Review
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
Tew et al. 2020
Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know
Della Corte et al. 2021 Expert Opin. Investig. Drugs 30: 543-554
Review
Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis
Ibrahim et al. 2020 Future Oncology 16: 585-596
Meta-Analysis
Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update
Tew et al. 2022 J Clin Oncol 40(33): 3878-3881
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Genemutated ovarian tumours: deﬁnition of homologous recombination deﬁciency?
Gourley et al. 2020 Curr Opin Oncol 32: 442-450

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

PARPs (Poly(ADP-Ribose) Polymerases) Inhibitors & Ovarian cancer

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat